Perceptive Pharma Research | Richmond, TX logo

Perceptive Pharma Research | Richmond, TX

Research site
About
Clinical trials
Location
7103 S PEEK RD A-110, Richmond, Texas, United States of America

Site insights

Top conditions

Top treatments

Etrasimod
BI 425809
KarXT
TEV-48574
ABX464
Valbenazine
Ralmitaront
SLS-002
Elafibranor
NRX-101

Parent organization

This site is a part of Perceptive Pharma Research

Data sourced from clinicaltrials.gov

Contact this site

Research coordinator

Verified by this site

Active trials

22 of 40 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: Etrasimod

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Other: Placebo
Drug: Guselkumab Dose 1

The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participant...

Active, not recruiting
Celiac Disease
Drug: TAK-062 Placebo
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose fi...

Enrolling
Rheumatoid Arthritis
Drug: SAR441566
Drug: Placebo
Locations recently updated

The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered e...

Enrolling
Colitis, Ulcerative
Crohn Disease
Drug: TEV-48574 Dose Regiment B
Drug: TEV-48574 Dose Regimen A

The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficac...

Enrolling
Colitis Ulcerative
Drug: Placebo
Drug: Dupilumab

The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's...

Enrolling
Colitis, Ulcerative
Crohn Disease
Drug: Placebo
Drug: TEV-48574

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as mainten...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Enrolling
Ulcerative Colitis
Drug: Etrasimod

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Invitation-only
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficac...

Enrolling
Ulcerative Colitis
Drug: SPH3127
Drug: Placebo

The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants...

Enrolling
Schizophrenia
Drug: Valbenazine
Drug: Placebo

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patie...

Enrolling
Major Depressive Disorder
Drug: ALTO-300
Drug: Placebo

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (...

Active, not recruiting
Primary Biliary Cholangitis
Drug: Bezafibrate 100 mg
Drug: Bezafibrate Placebo

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Scler...

Active, not recruiting
Pruritus
Drug: EP547
Drug: Placebo

Trial sponsors

AbbVie logo
Boehringer Ingelheim logo
A
Click Therapeutics logo
Karuna Therapeutics logo
Neurocrine Biosciences logo
Pfizer logo
Sanofi logo
Teva Pharmaceuticals logo
9

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems